Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
After graduating, he worked as an IT consultant for a listed company before becoming self-employed, during which time he worked for various DAX-listed companies and a large Swiss insurance company, among others.
Since 2009, he has been exclusively involved in the capital markets, where he was able to gain experience as a day and swing trader, in investor relations and at board level. He was able to live out his passion for numbers in the controlling department of a securities trading house.
For him, fundamental analysis paired with the correct reading of the price action of a market provides the basis for successful trading.
Commented by Armin Schulz
Commented by Armin Schulz on July 18th, 2025 | 07:10 CEST
Rheinmetall's boom in demand, Power Metallic Mines' key role in critical raw materials, and BYD in crisis?
The global hunt for strategic metals is driving markets into breathtaking volatility. Military expansion and the electromobility boom are driving demand for key raw materials, while geopolitical rifts pose a threat to supply. Whoever masters these bottlenecks controls future technologies and security-critical chains. Investors sense opportunities worth billions, but only a few players are positioning themselves decisively at the critical points. We therefore take a look today at Power Metallic Mines, an indispensable supplier, as well as Rheinmetall and BYD, which represent the raw material-hungry industries.
Read
Commented by Armin Schulz on July 17th, 2025 | 07:05 CEST
Bayer, NetraMark, Evotec: How AI Research is accelerating returns and could optimize your portfolio
In 2025, the healthcare industry is undergoing a radical transformation driven by AI and advanced technologies. While pharmaceutical giants struggle with cost pressures and regulatory hurdles, algorithms are revolutionizing drug development by decoding clinical data in record time and enabling personalized therapies. In this period of disruption, innovative strength will determine victory or decline. Three companies are at the forefront of this shift: Bayer, with its broad portfolio; NetraMark, leveraging AI-powered data analysis; and Evotec, with its disruptive research collaborations. Find out what is currently driving these stocks.
Read
Commented by Armin Schulz on July 16th, 2025 | 07:10 CEST
Novo Nordisk, BioNxt Solutions, BioNTech – How to heal your portfolio with the 2025 healthcare revolution
The global healthcare system is facing a turning point in 2025. Climate change, chronic diseases, and the scars left by pandemics are challenging existing systems, while digitalization and AI are rapidly advancing new therapies. Governments are investing billions in modern healthcare infrastructure, but debates about data protection and scheduling doctor's appointments are escalating. While the WHO warns of stagnation, groundbreaking alliances between research and industry are emerging. This is precisely where Novo Nordisk, BioNxt Solutions, and BioNTech come in with visionary technologies that not only heal but also open up opportunities for investors.
Read
Commented by Armin Schulz on July 16th, 2025 | 07:00 CEST
Nasdaq listing & USD 90 million: Almonty Industries plans its next steps and ensures further growth
With its move to the NASDAQ, Almonty Industries has completed its "Americanization". Following listings in Toronto and Sydney, the tungsten specialist is now in the spotlight of the largest capital markets. The stock market bell was probably heard in Beijing as well. The move to the NASDAQ is a logical step following the Company's relocation of its headquarters to Delaware and the appointment of high-ranking US military strategists to its board of directors. The 20 million new shares generated USD 90 million in revenue. The task now is to channel the money into mines, processing, and reserves in order to build up the entire value chain outside China. This scenario opens up opportunities for growth-oriented investors.
Read
Commented by Armin Schulz on July 15th, 2025 | 07:25 CEST
After tungsten, is this the next raw material bottleneck? thyssenkrupp, Pasinex Resources, and Mercedes-Benz under review!
Geopolitical tensions are forcing industrialized nations to radically rethink their strategies. Following strategic metals like tungsten and rare earths, another raw material is coming into the spotlight. The importance of steel refinement and high-tech production is growing exponentially, while supply risks are looming due to market concentration. Those who now secure alternative supply sources or develop substitution technologies will not only secure supply chains but also generate competitive advantages. We take a closer look at companies that rely on zinc, and one company that could help the US remove zinc from its list of critical raw materials.
Read
Commented by Armin Schulz on July 15th, 2025 | 07:15 CEST
Hydrogen at a crossroads: Plug Power, Pure Hydrogen, and Nel ASA between opportunity and crisis – Your profit strategy
The hydrogen industry is facing a critical turning point in 2025. Despite massive political support and growing global market volume, companies are struggling with profitability gaps and regulatory hurdles. The widening gap between ambition and implementation is becoming an existential threat. Only those who successfully master innovation, scalability, and infrastructure connectivity will survive the upcoming market shakeout. In this tense environment, it will be determined who can truly capitalize on the billion-dollar opportunities of green hydrogen – and who will be left behind. We take a look at Plug Power, Pure Hydrogen, and Nel ASA and analyze their path forward.
Read
Commented by Armin Schulz on July 14th, 2025 | 07:00 CEST
Capitalizing on the central bank gold rush: Barrick Mining's production, Dryden Gold's exploration, and Deutsche Bank's interest rate concerns
Gold is once again shining as a strategic anchor in turbulent times. Global central banks, especially those in emerging markets, are massively expanding their reserves, driven by geopolitical risks, currency diversification, and inflation concerns. At the same time, central banks like the ECB are lowering interest rates, which on the one hand offers banks cheaper refinancing, but on the other hand squeezes margins and increases credit risks. This dynamic mix of a gold rush, monetary policy shift, and inflationary pressure is forcing financial players to rethink their strategies. In this context, we take a look at two gold companies, Barrick Mining and Dryden Gold, and analyze the current outlook for Deutsche Bank.
Read
Commented by Armin Schulz on July 11th, 2025 | 07:05 CEST
Rheinmetall, Argo Graphene Solutions, Vonovia: Three beneficiaries of the EUR 500 billion stimulus package
Germany's economy is facing a billion-dollar gamble. Government super-write-offs and a EUR 500 billion special fund are fueling investment in infrastructure and defense. Record budgets of EUR 115 billion for roads, networks, and education, as well as EUR 86 billion for arms modernization, are creating unprecedented opportunities. Those who join now can benefit from Germany's largest restructuring in decades. But where are the best prospects? Today, we look at three companies that could profit from these investments in defense and infrastructure: Rheinmetall, Argo Graphene Solutions, and Vonovia.
Read
Commented by Armin Schulz on July 10th, 2025 | 07:15 CEST
How BioNTech, PanGenomic Health, and Pfizer are using artificial intelligence to cut costs and boost returns
Digitalization is revolutionizing the biotechnology and pharmaceutical industries. Artificial intelligence sifts through billions of pieces of medical data in real time, accelerating drug development by years. This is also demonstrated by the new alliance between Moderna and Google Cloud, which are jointly developing an AI platform for customized mRNA cancer therapies. These technologies reduce production costs by up to 40% and generate disruptive return opportunities. At the same time, personalized medicine is opening up billion-dollar markets. Three companies are turning to artificial intelligence to boost their returns: BioNTech, PanGenomic Health, and Pfizer.
Read
Commented by Armin Schulz on July 10th, 2025 | 07:05 CEST
Deutsche Telekom, MiMedia, Xiaomi: Three stocks benefiting from the cloud and AI revolution
By 2025, cloud services and artificial intelligence (AI) will become increasingly important. AI infrastructures have become a critical competitive nerve center. Hyperscaling and agentic systems are revolutionizing value chains; those who hesitate will lose out. The drivers are platforms such as Microsoft's new AI cloud generation, which enables the real-time integration of generative AI into core processes. This hyperscaling reduces costs, enhances data protection, and accelerates AI adoption in data-intensive sectors. A billion-dollar market is emerging for pioneers. Three players have strategically positioned themselves: Deutsche Telekom, MiMedia, and Xiaomi.
Read